68Ga-NOTA-Aca-BBN(7-14) PET显像在儿童视路胶质瘤中的应用
该前瞻性研究纳入8例MRI怀疑视路胶质瘤的儿童,行68Ga-NOTA-Aca-BBN(7-14)脑PET/CT或PET/MRI,其中4例同期行18F-FDG PET/CT对比。全部11个病灶均呈高摄取,肿瘤/背景比值显著高于18F-FDG,且SUV与GRPR表达水平正相关,PET/MRI导航平台可用于肿瘤勾画与手术规划。
要点
- 68Ga-NOTA-Aca-BBN(7-14) PET在儿童OPG中病灶检出率100%,对比度优良。
- 其SUVmax与SUVmean肿瘤/背景比值显著高于18F-FDG。
- SUV与GRPR表达水平正相关,PET/MRI可辅助手术规划。
核心结论
- 68Ga-NOTA-Aca-BBN(7-14) PET在儿童OPG中用于肿瘤检测和定位是可行的。
- 68Ga-NOTA-Aca-BBN(7-14) PET/MRI可能有助于重症OPG患者的手术规划。
- GRPR靶向PET有潜力为OPG患者后续GRPR靶向治疗提供影像引导。
研究设计与样本
- 前瞻性研究纳入8例MRI怀疑视路胶质瘤的儿童(5男,平均年龄8.81岁,范围5-14岁)。
- 静脉注射1.85 MBq/kg体重的68Ga-NOTA-Aca-BBN(7-14)后30分钟行脑PET/CT或PET/MRI。
- 其中4例另行18F-FDG脑PET/CT进行对比。
- 所有患者在1周内接受手术切除。
主要发现
- 8例患者的全部11个病灶(100%)均显示68Ga-NOTA-Aca-BBN(7-14)明显摄取,与周围正常脑组织对比优良。
- 68Ga-NOTA-Aca-BBN(7-14)的SUVmax和SUVmean肿瘤/背景比值分别为28.4 ± 5.59和18.3 ± 4.99,显著高于18F-FDG的0.47 ± 0.11和0.35 ± 0.07。
- 所有病灶病理确诊为OPG且GRPR表达阳性,其中75%为毛细胞型星形细胞瘤WHO I级,25%为弥漫型星形细胞瘤WHO II级。
- 68Ga-NOTA-Aca-BBN(7-14)的SUV与GRPR表达水平呈正相关(SUVmax r2 = 0.56,P < 0.01;SUVmean r2 = 0.47,P < 0.05)。
- 所有患者均通过PET/MRI导航平台获得用于肿瘤勾画的融合图像。
临床怎么用
- 对儿童OPG患者可考虑行68Ga-NOTA-Aca-BBN(7-14) PET/CT或PET/MRI进行肿瘤检测与定位。
- 68Ga-NOTA-Aca-BBN(7-14) PET/MRI融合图像可辅助重症OPG患者的手术规划。
- GRPR靶向PET显像结果可为OPG患者后续GRPR靶向治疗提供影像引导参考。
局限性
- 样本量小,仅纳入8例儿童患者。
- 仅4例患者进行了18F-FDG PET/CT对比。
- 研究为单中心前瞻性设计,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Optic pathway glioma (OPG) is a rare neoplasm that arises predominantly during childhood. Its location in a sensitive region involving the optic pathways, onset in young patients and controversial therapy choice make the management of OPG a challenge in paediatric neuro-oncology. In this study we assessed gastrin-releasing peptide receptor (GRPR)-targeted positron emission tomography (PET) imaging in children with OPG, and the application of a PET/MRI imaging-guided surgery navigation platform. METHODS: Eight children (five boys, mean age 8.81 years, range 5-14 years) with suspicion of optic pathway glioma on MRI were recruited. Written informed consent was obtained from all patients and legal guardians. Brain PET/CT or PET/MRI acquisitions were performed 30 min after intravenous injection of 1.85 MBq/kg body weight of 68Ga-NOTA-Aca-BBN(7-14). Four patients also underwent 18F-FDG brain PET/CT for comparison. All patients underwent surgical resection within 1 week. RESULTS: All 11 lesions (100%) in the eight patients showed prominent 68Ga-NOTA-Aca-BBN(7-14) uptake with excellent contrast in relation to surrounding normal brain tissue. Tumour-to-background ratios (SUVmax and SUVmean) were significantly higher for 68Ga-NOTA-Aca-BBN(7-14) than for 18F-FDG (28.4 ± 5.59 vs. 0.47 ± 0.11 and 18.3 ± 4.99 vs. 0.35 ± 0.07, respectively). Fusion images for tumour delineation were obtained in all patients using the PET/MRI navigation platform. All lesions were pathologically confirmed as OPGs with positive GRPR expression, and 75% were pilocytic astrocytoma WHO grade I and 25% were diffuse astrocytoma WHO grade II. There was a positive correlation between the SUV of 68Ga-NOTA-Aca-BBN(7-14) and the expression level of GRPR (r2 = 0.56, P < 0.01, for SUVmax; r2 = 0.47, P < 0.05, for SUVmean). CONCLUSION: This prospective study showed the feasibility of 68Ga-NOTA-Aca-BBN(7-14) PET in children with OPG for tumour detection and localization. 68Ga-NOTA-Aca-BBN(7-14) PET/MRI may be helpful for assisting surgery planning in OPG patients with severe symptoms, GRPR-targeted PET has the potential to provide imaging guidance for further GRPR-targeted therapy in patients with OPG.
引用
- Zhang J, Tian Y, Li D, et al. 68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma. Eur J Nucl Med Mol Imaging. 2019. PMID: 31270559. doi:10.1007/s00259-019-04392-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。